In the context of pharma maintenance, the focus of asset life cycle management should be on ensuring that the assets are maintained in good condition to support the safe, efficient, and effective production of pharmaceutical products. One of the key decisions that must be made in this context is the decision to recapitalize an asset, which involves replacing or upgrading it to maintain its performance and extend its life.
This presentation comprehensively addresses technical feasibility, economic viability, regulatory compliance, and operational impact, providing a comprehensive overview of our project’s core considerations.